NPA, cbdMD to outline CBD regulatory roadmap with virtual conference
The Natural Products Association and cbdMD are set to outline the CBD industry’s regulatory climate with a virtual conference. The “Regulatory Roadmap for the CBD Industry” conference is slated for Oct. 21 at 10 a.m. Various moderators who will participate in a Q&A with NPA CEO Daniel Fabricant.
Moderators include cbdMD counsel Lance Blundell, Owen Bennett of Jefferies, Rupesh Parikh from Oppenheimer and Ashol Kumar from ThinkEquity.
“The CBD industry is at an important stage in its development. Understanding the future regulatory climate is critical for CBD executives and their investors,” Blundell said. “Dr. Fabricant has a unique perspective on the future regulatory landscape and cbdMD is pleased to partner with the NPA to educate consumers, investors and distributors in this unique format.”
NPA has been pushing for CBD regulation by the Food and Drug Administration since 2017, has testified several times and held meetings with FDA officials about CBD regulation. The organization also helped create legislation passed by the House of Representatives that would allocate resources to enable the FDA to perform a health hazard evaluation and set a safe level for CBD for consumers to use every day.
The conference will be open only to participants invited at the sponsors’ request. Invitations requests can be made through Jefferies, Oppenheimer and ThinkEquity. The companies will share a transcript of the event on Oct. 26.
This article originally appeared in Drug Store News.
